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Abstract Short repeated cycles of peripheral ischemia/
reperfusion (I/R) can protect distant organs from subse-
quent prolonged I/R injury; a phenomenon known as re-
mote ischemic preconditioning (RIPC). A RIPC-mediated
release of humoral factors might play a key role in this
protection and vascular endothelial cells are potential tar-
gets for these secreted factors. In the present study, RIPC-
plasma obtained from healthy male volunteers was tested
for its ability to protect human umbilical endothelial cells
(HUVEC) from hypoxia–induced cell damage. 10 healthy
male volunteers were subjected to a RIPC-protocol con-
sisting of 4 9 5 min inflation/deflation of a blood pressure
cuff located at the upper arm. Plasma was collected before
(T0; control), directly after (T1) and 1 h after (T2) the RIPC
procedure. HUVEC were subjected to 24 h hypoxia dam-
age and simultaneously incubated with 5 % of the re-
spective RIPC-plasma. Cell damage was evaluated by
lactate dehydrogenase (LDH)-measurements. Western blot
experiments of hypoxia inducible factor 1 alpha (HIF1al-
pha), phosphorylated signal transducer and activator of
transcription 5 (STAT5), protein kinase B (AKT) and ex-
tracellular signal-related kinase 1/2 (ERK-1/2) were per-
formed. Furthermore, the concentrations of hVEGF were
evaluated in the RIPC-plasma by sandwich ELISA. Hy-
poxia–induced cell damage was significantly reduced by
plasma T1 (p = 0.02 vs T0). The protective effect of
plasma T1 was accompanied by an augmentation of the
intracellular HIF1alpha (p = 0.01 vs T0) and increased
phosphorylation of ERK-1/2 (p = 0.03 vs T0). Phospho-
rylation of AKT and STAT5 remained unchanged. Ana-
lysis of the protective RIPC-plasma T1 showed
significantly reduced levels of hVEGF (p = 0.01 vs T0).
RIPC plasma protects endothelial cells from hypoxia–in-
duced cell damage and humoral mediators as well as in-
tracellular HIF1alpha may be involved.
Keywords Remote conditioning  Human endothelium 
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Introduction
Transient episodes of ischemia (ischemic preconditioning),
if applied before prolonged ischemia/reperfusion injury,
are organ protective [12, 26]. Ischemic preconditioning
does not only act locally, but is also able to protect remote
tissues from ischemia/reperfusion injury, a phenomenon
described as remote ischemic preconditioning (RIPC).
RIPC can be induced by inflation and deflation of a blood
pressure cuff located at the upper or lower limb. This
procedure has been shown to attenuate organ injury in a
number of experimental and clinical situations [26, 27, 58].
Despite the encouraging results of RIPC in pre-
clinical and animal studies, a translation of RIPC into
the clinic is still not fully achieved [2, 16, 49, 57].
Nina C. Weber, Isabelle Riedemann have contributed equally to the
present publication.
N. C. Weber (&)  I. Riedemann  K. F. Smit 
D. van de Vondervoort  C. J. Zuurbier 
M. W. Hollmann  B. Preckel
Laboratory of Experimental Intensive Care and Anaesthesiology
(L.E.I.C.A.), Department of Anaesthesiology, University of
Amsterdam, Academic Medical Centre (AMC), Meibergdreef 9,
1100 DD Amsterdam, The Netherlands
e-mail: N.C.Hauck@amc.uva.nl
I. Riedemann  K. Zitta  M. Albrecht
Department of Anaesthesiology and Intensive Care Medicine,
University Hospital Schleswig-Holstein, Campus Kiel, Kiel,
Germany
123
Basic Res Cardiol (2015) 110:17
DOI 10.1007/s00395-015-0474-9
However, there are several clinical trials in progress
elucidating the potential clinical benefit of RIPC. In
patients undergoing coronary artery bypass graft
(CABG) surgery an acute and probably favourable at-
tenuation of cardiac enzyme release has been demon-
strated, and thus there is evidence that RIPC provides
perioperative myocardial protection and improves the
prognosis of these patients [9, 68, 69]. Similar protec-
tive effects could also be found in patients undergoing
elective percutaneous coronary intervention (PCI) [14,
34] and ST-elevation myocardial infarction (STEMI)
patients undergoing primary PCI [5, 65]. On the other
hand, deleterious effects with a significant increase in
cardiac injury have been described [10, 37, 59].
Therefore, the results of the large clinical trials ongoing
in CABG patients [22, 50] will substantially increase
our knowledge about the translatability of RIPC in the
clinical setting.
The underlying mechanisms of RIPC have been at-
tributed to humoral, neuronal and anti-inflammatory path-
ways [27]. However, the exact mechanisms are complex
and yet not completely understood [24, 62]. It is suggested
that the humoral mediators might be released from the
remote tissue into the blood stream from where they are
transported to the target organ, and/or that they are pro-
duced after stimulation via neuronal pathways in the target
organ itself [24, 47]. In the last years, several so far
unidentified mediators of RIPC have been described by
different groups: e.g. stomal derived factor (SDF) 1alpha
[6], exosomes [19], Apolipoprotein A1 [32], miR144 [45],
IL-10 [8], matrix metalloproteinases (MMPs) [74] and ni-
trite [60]. For review, also see [27].
For several reasons the vascular endothelium, espe-
cially in the target organ, could play a central role in the
RIPC-mediated mechanisms of organ protection from I/R
injury: (1) humoral factors that are released into the blood
stream upon RIPC stimulus may directly interact with
endothelial cells which in turn may directly or indirectly
transfer the RIPC stimulus to the underlying tissue [51].
(2) Endothelial cells are among the first cell types that
will encounter hypoxia in the target organ and respond to
it [63]. (3) Endothelial dysfunction is a major reason for
severe local and systemic consequences of I/R injury [63].
Moreover, it has been demonstrated that RIPC before
primary percutaneous coronary intervention significantly
improves endothelial function in patients with acute my-
ocardial infarction, and this effect remains constant for at
least a week [48]. These data suggest that the improve-
ment of endothelial function may be one possible expla-
nation for the protective effects of RIPC. In this context it
is worth mentioning that the coronary circulation and
cardiac remodelling that are directly related to the en-
dothelial function just recently have been recognized to
be critical determinants of cardioprotective interventions
[28, 29].
In the present study, RIPC-plasma was obtained from
healthy male volunteers and tested for its ability to protect
human vascular endothelial cells (HUVEC) from hypoxia–
induced cell damage. We furthermore investigated the
cellular target mechanisms that were affected by RIPC-
plasma in HUVEC cells subjected to a hypoxic insult.
Materials and methods
Chemicals, solutions and culture media
If not otherwise stated all chemicals and solutions were
purchased either from Roche (Almere, the Netherlands),
Sigma-Aldrich (Zwijndrecht, Netherlands), Merck (Milli-
pore, Amsterdam, Netherlands) or Carl Roth (Karlsruhe,
Germany).
Isolation of human umbilical vein endothelial cells
(HUVEC)
HUVEC were freshly isolated from umbilical cords as
described previously [71] (Waiver: W12-167#12.17.096,
Ethical committee Amsterdam) and maintained in a hu-
midified atmosphere of 5 % carbon dioxide/95 % air at
37 C in ECGM medium supplemented with endothelial
cell growth supplement (Promocell Bio-Connect, Huizen,
Netherlands), 1 % penicillin/streptomycin, 1 % ampho-
tericin B and 10 % heat-inactivated foetal bovine serum
(PAA, Germany, Freiburg). All culture surfaces were
coated with 0.75 % gelatine (BD Diagnostic Systems,
Netherlands, Breda) prior to cell seeding. Only cells from
passage 3 were used in the experiments. Characterization
of HUVEC cells was performed by detection of von
Willebrand-factor by fluorescence staining and fluores-
cence activated cell sorting FACS (data not shown).
Collection of human plasma
The study was approved by the local ethics committee of
the Academic Medical Centre (AMC), University of
Amsterdam, The Netherlands, (ISRCTN59201440) and
was performed in accordance with the Declaration of
Helsinki and the Medical Research Involving Human
Subjects Act. Ten healthy male volunteers
(25.20 ± 3.39 years) were subjected to a RIPC-protocol
consisting of 4 9 5 min inflation/deflation of a blood
pressure cuff located at the upper right arm. Prior to par-
ticipation, all subjects gave their written informed consent.
The following inclusion criteria were chosen: (1) healthy,
(2) male, (3) age between 18 AND 45 years. Exclusion
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criteria were as follows: (1) cardiovascular, kidney, pul-
monary or endocrine diseases, (2) alcohol or drug abuse,
and (3) no informed consent. We decided to only include
male volunteers into the study to avoid potential influences
of oestrogens [56]. Subject characteristics are given in
Table 1.
Blood was collected before (T0; baseline time point
prior to inflation of blood pressure cuff = controls), di-
rectly after (T1) and 60 min after (T2) the RIPC-protocol
(Fig. 1). The blood samples were collected in citrate vials
(BD bioscience, Breda, The Netherlands) and centrifuged
at 4 C, 290 g for 10 min. Plasma was aliquoted, and
stored at -80 C.
To evaluate the optimal concentration of human plasma
to be added to the culture medium, HUVEC cells were
incubated with different concentrations (0, 1, 5, 10 %) of
fetal bovine serum and growth characteristics as well as the
degree of hypoxia–induced cell damage were evaluated.
On the basis of these results, the optimal concentration of
plasma was selected. A similar approach has also been
chosen in our recently published study in which RIPC
serum was used [74]. These evaluations suggested that the
basic culture medium should be supplemented with 5 %
plasma.
Induction of in vitro hypoxia in HUVEC by enzymatic
oxygen depletion
Hypoxic conditions in HUVEC were induced using a
modified version of our recently described enzymatic
model [36, 75]. In the present study concentrations of the
hypoxia inducing enzymes were adapted to 4 U/ml glucose
oxidase (GO), and 120 U/ml catalase (CAT) and cell cul-
ture plates were transferred into an airtight chamber, which
was flooded with 1 bar, 10 l/min nitrogen gas until oxygen
was reduced to 1 %. The box was then kept inside an in-
cubator at 37 C. Oxygen levels were monitored directly in
the culture medium using an OxyMini fibre optic oxygen
meter (World Precision Instruments, USA, Sarasota) and
OxyMicro Software v.00 04/2003.
Experimental protocol
HUVEC cells were seeded into gelatine-coated 12 well
plates 2 days before the experiment. At the beginning of
the experiment ECGM growth medium was exchanged
and cells were pre-incubated for 1 h with M199 medium
(PAN Biotech, Aidenbach, Germany) containing 5 % of
the respective RIPC-plasma (T0, T1, T2). Subsequently,
the normoxic medium was replaced by hypoxic M199
containing 5 % of the respective RIPC-plasma and the
culture plates were placed in an airtight chamber and
kept inside an incubator for 24 h. For colorimetric lactate
dehydrogenase (LDH)-measurements the cell culture
medium of each well was collected after 24 h of hypoxia
and frozen at -20 C. For Western blotting experiments
the cells were harvested and frozen at -80 C (Fig. 1).
Determination of cell death
LDH activity was colorimetrically evaluated using a Lac-
tate Dehydrogenase Activity Assay Kit (Biovision,
Uithoorn, Netherlands,) following the manufacturer’s pro-
tocol. Absorbance was measured before and after 30 min
of incubation (37 C) at 450 nm using an ELISA reader
(Tecan, Crailsheim, Germany).
Western blotting
Western blotting was performed as described previously
[74]. Overnight incubation of the membranes was con-
ducted at 4 C with appropriate dilutions of primary anti-
bodies directed against HIF1alpha (Acris, Novus
Biological, Herford, Germany, 1:1000), actin (Santa Cruz,
Heidelberg, Germany, 1:1000), pAKT (Cell Signalling,
Danvers, USA, 1:1000), AKT (Cell Signalling, Danvers,
USA, 1:2000), pERK-1/2 (Cell Signalling, Danvers, USA,
1:8000), ERK-1/2 (Cell Signalling, Danvers, USA,
1:8000), pSTAT5 (R&D Systems, Wiesbaden-Nordenstadt,
Germany, 1:1000), or against STAT5 (R&D Systems,
Wiesbaden-Nordenstadt, Germany, 1:1000). Membranes
were rinsed three times for 10 min with tris-buffered saline
plus tween buffer (TBST) at room temperature, and were—
depending on the primary antibody used—incubated for
1 h with the secondary horseradish peroxidase coupled-
antibody (anti-rabbit, DAKO, Eching, Germany, 1:10,000
or anti-goat, Santa Cruz, Heidelberg, Germany, 1:10,000),
with a biotin coupled-antibody (anti-rabbit, Abcam, Cam-
bridge, UK, 1:10,000), or with horseradish peroxidase-
coupled streptavidin for the biotinylated secondary
Table 1 Summarized volunteer data
Volunteer identification # 1 2 3 4 5 6 7 8 9 10 Mean SD
Age [years] 26 21 19 27 28 24 27 23 30 27 25.20 3.39
Height [m] 1.80 1.85 1.85 1.95 1.90 1.82 1.93 1.80 1.86 1.75 1.85 0.06
Weight [kg] 74 85 80 95 85 73 95 70 73 78 80.80 9.02
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antibody (AbD Serotec, Puchheim, Germany, 1:5000).
After washing three times with TBST buffer for 10 min,
the membranes were incubated with ECL detection reagent
(GE Healthcare Life Sciences, Freiburg, Germany) for
5 min. For signal detection, autoradiography films (GE
Healthcare Life Sciences, Freiburg, Germany) were ex-
posed to the membranes for various time periods in the
dark. Relative intensities of protein bands were analysed by
ImageJ v1.48 and GraphPad Prism 5.0 for Mac. In some
experiments, membranes were stripped and re-probed with
different antibodies. Therefore, the membranes were in-
cubated for 15 min at 56 C with stripping buffer (4 ml
SDS 10 %, 2.5 ml Tris 0.5 M pH 6.8, 13.5 ml ultrapure
water, 160 ll 2-mercaptoethanol). After washing with
TBST buffer, the membranes were re-blocked with 3 %
BSA/TBST buffer for 1 h and were washed three times
with TBST buffer.
Quantification of human vascular endothelial growth
factor
The concentrations of the human Vascular Endothelial
Growth Factor (hVEGF) were determined in RIPC-plasma
by specific ELISA systems, (ScienceCell Research
Laboratories, USA, Carlsbad) according to the manufac-
turer’s protocol. Absorbance was measured at 450 nm us-
ing an ELISA reader (Tecan, Germany, Crailsheim) and
hVEGF concentrations were calculated from the standard
curve provided.
Statistical analysis
Statistics were performed using the software GraphPad
Prism 5.0 for Mac. D’Agostino normality testing was used
to check data for normal distribution. Parametric data were
analysed using One-Sample t-Tests (LDH-activity,
hVEGF) or Paired t-Tests (HIF1alpha, pSTAT5). Non-
parametric data were analysed using the Wilcoxon signed
rank test (pAKT, pERK-1/2). Variables are expressed as
mean ± SEM.
Results
Plasma obtained directly after RIPC reduces
the hypoxia–induced cell damage in HUVEC cells
LDH-assays were used to evaluate the influence of RIPC-
plasma (T1, T2) on hypoxia–induced cell damage of
HUVEC cells. T0-plasma, obtained prior to RIPC, was
used as baseline control. Mean LDH-activity in the culture
media at baseline was 7.58 ± 0.9 mU/ml, while the range
of LDH activity varied between different samples (mini-
mum LDH: 1.50 mU/ml, maximum LDH: 15.24 mU/ml;
Fig. 2a) Compared to plasma T0, plasma T1 significantly
reduced the hypoxia–induced cell damage (T1:
0.89 ± 0.04; T0 = 1; p = 0.02; Fig. 2b). Plasma T2 did
not significantly change the hypoxia induced damage in
HUVEC cells (T2: 1.04 ± 0.03; T0 = 1; p = 0.15;
Fig. 2b).
The reduction of hypoxia–induced cell damage
by RIPC-plasma is associated with an increased protein
expression of HIF1alpha and enhanced phosphorylation
of ERK-1/2
Using Western blotting, the expression of several proteins
potentially involved in RIPC-mediated organ protection
Fig. 1 Experimental setting. The RIPC-protocol consisted of
4 9 5 min inflation/deflation of a blood pressure cuff. Plasma was
obtained before (T0), directly after (T1) and 60 min after (T2) the
RIPC stimulus. HUVEC cells were incubated with the respective
plasma and subjected to 24 h of hypoxia. Employing cell culture
media and cell lysates, cell damage as well as cellular signalling
events were investigated. H hypoxia; green color, RIPC-plasma
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was investigated [21, 24, 39]. As only plasma T1 but not T2
was able to significantly reduce hypoxia–induced cell
damage in HUVEC cells (Fig. 2), all Western blotting
experiments were performed with HUVEC cells incubated
with T1 and the respective control plasma (T0). Den-
sitometric analyses revealed no statistically significant
differences in the phosphorylation of AKT in HUVEC cells
that were incubated with plasma T1 (T1: 0.12 ± 0.04 ar-
bitrary units (a.u.) versus T0: 0.16 ± 0.1 a.u.; p = 0.85;
Fig. 3a) or STAT5 (T1: 0.53 ± 0.1 a.u. versus T0:
0.65 ± 0.1 a.u.; p = 0.10; Fig. 3b). However, plasma T1
significantly augmented the amount of HIF1alpha (T1:
0.79 ± 0.2 a.u. versus T0: 0.43 ± 0.1 a.u.; p = 0.01;
Fig. 3c) and increased the phosphorylation of ERK-1/2
(T1: 0.66 ± 0.3 a.u. versus T0: 0.29 ± 0.1 a.u.; p = 0.03;
Fig. 3d) in HUVEC cells that were exposed to 24 h of
hypoxia. Control studies revealed that the significant in-
crease in HIF1alpha expression and the significantly in-
creased phosphorylation of ERK-1/2 that were detected
after the addition of protective plasma T1 was not evident
when employing the non-protective plasma T2 (data not
shown).
Concentrations of VEGF are reduced in protective
RIPC-plasma T1
As VEGF is discussed to be a humoral factor involved in
RIPC-mediated organ protection [11, 13, 55], we evaluated
the concentrations of human VEGF (hVEGF) in RIPC
plasma using a sandwich ELISA system. Mean hVEGF
concentrations in plasma T0 were 67.91 ± 32.9 pg/ml,
while the range of hVEGF varied between plasma samples
of different donors (minimum hVEGF: 8.26 pg/ml, max-
imum hVEGF: 352.80 pg/ml; Fig. 4a) Concentrations of
hVEGF were significantly reduced in the protective plasma
(T1) which was derived directly after RIPC (T1:
0.87 ± 0.04; T0 = 1; p = 0.01; Fig. 4b).
Discussion
The major findings of the present study are the following:
(1) human plasma retrieved directly after remote ischemic
preconditioning (RIPC) is able to reduce hypoxia–induced
damage of human endothelial cells cultured in vitro. (2)
Expression of HIF1alpha but not phosphorylation of ERK-
1/2, AKT or STAT5 seems to be involved in the protective
effects of RIPC-plasma. (3) The protective RIPC-plasma
contains decreased amounts of VEGF.
To date, the exact mechanisms of RIPC are not fully
understood. However, three hypotheses to explain the
phenomenon of remote ischemic organ protection have
been established: (1) RIPC triggers the release of humoral
factors into the bloodstream from where they reach the
remote target organ; (2) neuronal pathways confer the
RIPC-protection; and (3) a systemic anti-inflammatory and
anti-apoptotic response is induced by the RIPC stimulus
[24, 62]. Recently, several circulating mediators have been
identified, e.g. stromal derived factor (SDF) 1alpha [6],
exosomes [19], Apolipoprotein A1 [32], miR144 [45], IL-
10 [8], or nitrite [60] that may be involved in RIPC-me-
diated cell and organ protection. Using an in vitro ap-
proach, we showed that serum from cardiac surgical RIPC
patients as well as culture media from hypoxia–conditioned
HUVEC cells are both able to reduce hypoxia–induced cell
damage in intestinal cell cultures [36, 74]. These results
underline the potential role of secreted factors for RIPC-
mediated organ protection. Here we extended our recent
Fig. 2 Effects of RIPC-plasma on hypoxia–induced damage of
HUVEC cells. a Quantification of LDH-activities as a marker for
cell damage in HUVEC cell culture media. Culture media were
supplemented with 5 % plasma (T0, T1 and T2) from the various
volunteers (#1–#10) and LDH-activities were measured after 24 h of
hypoxia. b Relative LDH-activities in culture media of HUVEC cells
after 24 h of hypoxia. Cell culture media were supplemented with
plasma T0, T1 or T2. Hypoxia–induced cell damage is significantly
reduced by the addition of plasma T1. Numbers in the columns show
the numbers of different plasma samples used. Columns display the
mean ± SEM
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studies and applied RIPC-plasma, which was retrieved
from healthy male volunteers, to cultured endothelial cells.
In our study, plasma from RIPC volunteers (obtained
before, directly after and 60 min after RIPC) was added to
the HUVEC cell cultures 1 h before the hypoxic insult and
cells were incubated with plasma-substituted medium for
24 h. It is known that ischemic preconditioning [42] rep-
resents a biphasic phenomenon with a first and a second
window of protection [35] and similar mechanisms may
also be effective in RIPC. The early phase of protection
develops quickly within minutes from the initial ischemic
conditioning event and lasts for 2–3 h. This is followed by a
delayed phase that begins after 12–24 h and lasts up to
4 days. The mechanisms of the two phases of precondi-
tioning are rather different. While the early phase is caused
by rapid release or modification of pre-existing proteins, the
delayed phase requires synthesis of new proteins [43, 44].
Our present findings showing cytoprotective effects of
RIPC-plasma that was obtained directly after RIPC, but not
of plasma derived 60 min after RIPC is somewhat in
Fig. 3 Effects of RIPC-plasma on protein expression and phospho-
rylation in HUVEC cells exposed to hypoxia. a Phosphorylation of
AKT; b phosphorylation of STAT5; c expression of HIF1alpha;
d phosphorylation of ERK-1/2. e Western blotting experiments
performed with lysates of HUVEC cells that were treated with RIPC-
plasma samples (#1–#10). Numbers in the columns show the numbers
of different plasma samples used. Columns display the mean ± SEM
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contrast to the above mentioned studies, clinical observa-
tions and also to our previous publication in intestinal cells
(subjected to a hypoxic insult) [74]. However, in the frame
of our previous study, RIPC sera were collected from
mostly older cardiac surgical patients, while in the study
presented here, 10 young and healthy donors were inves-
tigated. Several authors have shown that age, diet, hor-
monal status, comorbidities and other factors may influence
and modify the protective potential of ischemic condi-
tioning [1, 15, 17, 53]. Furthermore, the observation that
only plasma that was derived directly after RIPC protected
HUVEC cells from hypoxia–induced cell damage could be
related to the half-life of the responsible factor(s). Potential
mediators that might transfer the RIPC protection are
adenosine [52, 61, 66], bradykinin [38, 61], opioids [67] as
well as matrix MMPs [46, 73, 74] for review see [41], all of
which have a limited half-life in circulation [54] and cell
culture [18] and—especially in the case of MMPs—can be
modified and/or degraded by other proteases [6, 73].
It should also be mentioned that while other authors
employed serum [74], in the study presented we used
plasma from RIPC treated volunteers. Compared to
serum, plasma contains clotting factors such as fibrino-
gen but is deficient of mediators that are released from
blood cells (mainly thrombocytes) upon coagulation.
There is no evidence that these molecules interfere with
RIPC-mediated processes and we therefore do not expect
differences in the protective potential of serum in com-
parison to plasma.
Taken together, although we do not have a clear ex-
planation why plasma obtained 60 min after RIPC was not
effective in protecting HUVEC cells from hypoxia–in-
duced cell damage in the study presented, individual
characteristics (age, gender, hormonal status, diet, etc.) of
the plasma donors and the use of an in vitro culture system
(devoid of e.g. immune cells, humoral factors, blood cir-
culation, etc.) may at least partially be responsible for this
observation. Moreover, not all aspects of ischemia/reper-
fusion injury as they appear in vivo can be reflected using
this in vitro system. However, the cell culture model en-
ables us to reproducibly investigate isolated events of is-
chemia/hypoxia and the associated cellular as well as
molecular mechanisms, which is probably the biggest ad-
vantage over animal and clinical studies.
Regarding the mechanisms that are induced by RIPC in
the target cells, we found an increased amount of
HIF1alpha protein in hypoxia stressed HUVEC cells that
were treated with plasma derived directly after RIPC.
HIF1alpha acts as an oxygen-regulated transcription factor
controlling oxygen homeostasis [64] and activation of
HIF1alpha leads to induction of target gene activation of
e.g. erythropoetin, hexokinase 1 and 2, iNOS and VEGF
[33]. Although little is known about the precise role of
HIF1alpha in RIPC, several studies proposed an involve-
ment of the protein in ischemic preconditioning [7, 25, 64].
However, there is also a study suggesting that upregulation
of HIF1alpha in limb is not associated with myocardial
protection of early RIPC and might only act locally [40].
Employing cardiac tissue of cardiosurgical patients that
received RIPC or sham intervention, we recently showed
that HIF1alpha expression was significantly increased in
cardiac tissue of RIPC patients [3], pointing towards pos-
sible organ protective effects of enhanced HIF1alpha ex-
pression. The protective role of HIF1alpha is also
supported by our preliminary experiments employing the
HIF1alpha inhibitor LY294002 (10 lM) [72] which
showed that the cytoprotective effects of plasma T1 are
attenuated by inhibiting the translation of HIF1alpha.
Fig. 4 Quantification of hVEGF concentrations in human RIPC-plasma. a hVEGF concentrations in RIPC-plasma T0 and T1. b Relative hVEGF
concentrations in T1-plasma. Numbers in the columns show the numbers of different plasma samples used. Columns display the mean ± SEM
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Besides an enhanced expression of HIF1alpha, phos-
phorylation of ERK-1/2 was increased in hypoxia stressed
HUVEC cells that were treated with plasma derived di-
rectly after RIPC. It is known that phosphorylation of ERK,
being part of the pro-survival MAPK/ERK-pathway, re-
sults in inhibition of the pro-apoptotic Bad and is thus
impeding the process of apoptotic cell death [20, 62]. In
HUVEC cells, transient hypoxia can induce anti-apoptotic
events and increase cell survival via ERK-dependent
pathways [20] and in the porcine heart RIPC effects are
also associated with augmented levels of phosphorylated
ERK-1/2 [23]. Interestingly, our preliminary data em-
ploying the ERK kinase inhibitor PD98059 (10 lM) in
combination with the protective plasma T1 did not confirm
an involvement of ERK-1/2 in our in vitro setting, as the
inhibition of ERK-1/2 phosphorylation did not result in
increased cell damage measured by LDH activity. We
propose that further work is necessary to elucidate the
precise role of ERK-1/2 activation in RIPC-mediated cy-
toprotection, especially in endothelial cells.
Hausenloy et al. [23] not only reported pERK-1/2 to be
involved in RIPC-mediated organ protection, but also
pAKT. Similar to pERK-1/2, pAKT is involved in cellular
survival pathways: the PI3 K/AKT-pathway, also known as
‘‘reperfusion injury salvage kinase (RISK) pathway’’,
phosphorylates and thereby inactivates the pro-apoptotic
Bad leading to an inhibition of apoptosis [39, 62]. Inter-
estingly, in the present study we did not observe an in-
creased phosphorylation of AKT, which might indicate that
different cell types (e.g. myocardial cells versus endothelial
cells) respond differently to the RIPC stimulus.
In the literature, the involvement of STAT5 in RIPC is
discussed controversially. While an increased phosphory-
lation of STAT5 was described in ventricular cells after
RIPC in humans [31], other authors did not find alterations
in STAT5 phosphorylation using cultured intestinal cells
[36]. From recent studies it appears that STAT3 and
STAT5 might have reverse functions in animals and hu-
mans: STAT5 but not STAT3 activation is associated with
protection in humans [31], whereas STAT3 activation and
possibly STAT5 inhibition are associated with protection
in animals [30]. In a clinical trial with RIPC patients un-
dergoing coronary artery bypass surgery, Heusch et al. [31]
have shown that the phosphorylation of STAT5 increased
from baseline before ischemic cardioplegic arrest to
10 min of reperfusion with RIPC, and that STAT5 phos-
phorylation during reperfusion was greater in patients with
RIPC than in control patients. Once more, the target organ
and/or target cell type might determine which signalling
pathways are induced via RIPC and this might explain the
lack of STAT5 phosphorylation in the context of our study.
Concerning possible factors transferring the RIPC signal
to the target cells, VEGF could be a potential candidate
[11, 13, 55]. Several studies suggested that VEGF reduces
ischemic damage via ERK-1/2 dependent pathways [11,
13]. Surprisingly, in our study employing RIPC-plasma in
combination with a cell culture system, VEGF specific
ELISAs revealed significantly reduced levels of the protein
in protective RIPC plasma. In the first place these data
would suggest that VEGF is not involved in RIPC-medi-
ated protection of endothelial cells. However, VEGF in-
fluences endothelial cell proliferation and migration and
has been reported to stimulate the expression of metallo-
proteinases (MMPs) in HUVEC cells [4, 70]. We have
recently shown that activities of MMP-2 and MMP-9 are
reduced by RIPC in cardiac tissue of cardiosurgical pa-
tients [73]. These findings suggest that MMPs could be
involved in RIPC and VEGF mediated mechanisms, how-
ever, further studies are needed to confirm a potential
causal relationship between RIPC, VEGF and MMPs.
In conclusion, the results of the present study support
the hypothesis that humoral factors confer RIPC-mediated
cell and organ protection and we suggest endothelial cells
as targets for RIPC-released mediators.
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